Data and code from: Microfluidic nanomagnetically isolated neuron- and astrocyte-derived extracellular vesicles to differentiate Lewy body and Alzheimer’s disease

Identifying plasma-based biomarkers that can accurately differentiate Lewy
body disease (LBD) from Alzheimer’s disease (AD) remains a major
challenge. Extracellular vesicles (EVs), which carry molecular cargo from
their parent cells and can cross the blood-brain barrier, offer a new path
forward. We developed the multiplexed Track-Etch magnetic NanoPOre
(mTENPO) platform, a highly parallelized microfluidic technology for
cell-specific EV isolation, and demonstrated independent enrichment of
GluR2+ (neuron-derived) and GLAST+ (astrocyte-derived) EVs from the
antemortem plasma of 137 autopsy-confirmed LBD, AD, mixed pathology, and
control subjects. By integrating miRNA sequencing of GluR2+ and GLAST+ EV
cargo with plasma measurements of Aβ40, Aβ42, tau, p-Tau181, and p-Tau231,
we identified a multimodal 15-feature panel that more comprehensively
reflects brain pathology than conventional biomarkers. Using 10-fold
cross-validation to mitigate overfitting, the panel achieved an accuracy
of 0.95 and an area under the curve of 0.96 for distinguishing LBD versus
AD.